Objective To investigate the clinical effect of apatinib combined with icotinib in the treatment of epidermal growth factor receptor(EGFR)gene exon 21 L858R mutant non-small cell lung cancer(NSCLC).Methods 101 patients with EGFR gene exon 21 L858R mutant NSCLC were divided into the observation group(n =51)and the control group(n =50)by random number table method.The observation group was treated with apatinib combined with icotinib,and the control group was treated with icotinib for 56 days(2 cycles).Short-term efficacy and adverse reactions were compared between the 2 groups.Long-term efficacy in the 2 groups was analyzed using the K-M survival analysis curve.Results There was no statistically significant difference between the observation group and the control group in terms of the objective response rate(ORR)(74.51%vs.74.00%)and disease control rate(DCR)(92.16%vs.94.00%)(P>0.05).No adverse reactions above grade2 were observed in either group.The incidence rates of hypertension and proteinuria in the observation group(52.94%and 50.98%)were higher than those in the control group(16.00%and 10.00%)(P<0.05).The survival rate in the observation group was significantly higher than that in the control group(69.3%vs.43.1%)(P<0.05).Conclusion Applying apatinib combined with icotinib to treat patients with EGFR gene exon 21 L858R mutant NSCLC can prolong their progression free survival time,and the adverse re-actions are acceptable.
维普
万方数据
